Mov Disord: Extracellular vesicles in the blood, which can effectively diagnose Parkinson's

Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative diseases characterized by the pathological accumulation of α-synuclein in cells, called Lewy bodies

In contrast to PD and DLB, the neuropathological feature of progressive supranuclear palsy (PSP) is the intracellular accumulation of the microtubule-associated protein tau

So far, the diagnostic biomarkers for PD include structural and functional imaging, as well as the analysis of cerebrospinal fluid (CSF) alpha-synuclein at an experimental level, which is reduced in PD

Less invasive biomarkers are preferable to CSF ​​markers.

Biomarkers should best reflect the main aspects of the basic pathology of the disease

Alpha-synuclein is released together with EVs in vitro and in vivo

In this way, Anne Stuendl and others of the University of Bonn in Germany explored the diagnostic potential of plasma EV-related α-synuclein for PD and DLB (another α-synuclein-related neurodegenerative disease), PSP (a non- Differential diagnosis of α-synuclein-related atypical Parkinson's disease), healthy controls (HCs) and nervous system controls (NCs)

They first established an optimized detection method for preparing plasma extracellular capsules and detecting α-synuclein derived from extracellular capsules

They found that the concentration of α-synaptic nucleotides in plasma extracellular vesicles had the best distinction between PD, Lewy body dementia, PSP and healthy controls

Specifically, in the Tubingen cohort, the area under the curve was 0.